Research Paper Volume 16, Issue 10 pp 8822—8842
Inflammation-based lung adenocarcinoma molecular subtype identification and construction of an inflammation-related signature with bulk and single-cell RNA-seq data
Figure 5. Responsiveness of risk score to PD-L1 blockade immunotherapy in the IMvigor210 and GSE78220 cohorts. (A) Prognostic difference among the risk score groups in the IMvigor210 cohort. (B) Differences in risk scores among immunotherapy responses in the IMvigor210 cohort. (C) Distribution of immunotherapy responses among the risk score groups in the IMvigor210 cohort. (D, E) Prognostic difference between the risk score groups in patients with early or advanced stage disease in the IMvigor210 cohort. (F) Prognostic difference among the risk score groups in the GSE78220 cohort. (G) Differences in risk scores among immunotherapy responses in the GSE78220 cohort. (H) Distribution of immunotherapy responses among the risk score groups in the GSE78220 cohort. ***P <0.001, ****P < 0.0001.